🔍

ASTERDM - Aster DM Health.

📊 NSE: ASTERDM 🏢 Healthcare 📅 Last Updated: 12/13/2025 18:39

📢 Recent Corporate Announcements

Aster DM Reports ₹17.69 Cr Revenue Loss Due to Kerala Nurse Strike; High Court Intervenes

🔴 NEGATIVE ⭐ 7/10

OTHER 📅 14 Mar 2026, 02:24 PM

Aster DM Healthcare has reported a revenue loss of ₹17.69 crore between March 8 and March 13, 2026, due to a statewide nurse strike in Kerala affecting seven of its hospitals. The Kerala High Court has intervened, directing the United Nurses Association to defer the strike until March 19 and move to mediation for wage negotiations. The company anticipates a further potential loss of ₹5.33 crore if the situation resolves by the court-mandated deadline. Management has activated contingency plans, including mobilizing staff from Karnataka, to maintain critical services.

Reported revenue loss of ₹17.69 crore from March 8 to March 13, 2026
Estimated additional loss of up to ₹5.33 crore expected until March 19
Kerala High Court ordered a temporary halt to the strike and referred the dispute to mediation
Strike affected seven major hospitals including Aster Medcity and MIMS units in Kerala
Company mobilized nursing staff from neighboring Karnataka to ensure continuity of critical care

💡 Investors should monitor the mediation outcome on March 19, as a permanent wage hike could impact long-term margins in the Kerala cluster. The current financial impact is manageable but highlights labor risks in a core operating region.

Aster DM Seeks Approval for Dr. Azad Moopen's Appointment & INR 1,500 Cr Loan Limit

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 13 Mar 2026, 10:01 PM

Aster DM Healthcare has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Mandayapurath Azad Moopen as Executive Director from April 2026 to May 2028. The proposed annual remuneration is capped at INR 10 Crores, which may be paid even in the event of inadequate profits. Furthermore, the company is seeking a mandate to provide loans, guarantees, or securities up to INR 1,500 Crores to its subsidiaries and group entities. This financial limit is intended to support the growth of its core hospital, pharmacy, and diagnostic business segments over the next three years.

Proposed appointment of Dr. Mandayapurath Azad Moopen as Executive Director for the period April 15, 2026, to May 28, 2028.
Annual remuneration for the Executive Director capped at INR 10 Crores, including fixed salary and variable pay.
Seeking shareholder approval for a loan and guarantee limit of up to INR 1,500 Crores for group entities under Section 185.
The INR 1,500 Crore limit will be valid for three years and restricted to core healthcare business activities.
Remote e-voting period is scheduled from March 14, 2026, to April 12, 2026, with results by April 14.

💡 Investors should monitor the voting results and subsequent deployment of the INR 1,500 Crore loan limit to ensure capital is used for high-return healthcare expansions. The continuation of the founder's leadership provides stability, though the high remuneration cap during potential profit lean periods should be noted.

Aster DM Shareholders Approve Merger with Quality Care India with 96.68% Majority

🟢 POSITIVE ⭐ 10/10

M&A 📅 11 Mar 2026, 10:21 PM

Aster DM Healthcare has received a decisive 96.68% shareholder approval for its proposed merger with Quality Care India Limited (QCIL). The combined entity, to be named Aster DM Quality Care Ltd, will emerge as one of India's top three hospital chains with a massive capacity of over 10,625 beds. The transaction has already secured CCI and Stock Exchange clearances and is expected to be fully completed in the next quarter following final NCLT approvals. This merger, backed by Blackstone, significantly scales the company's operations to 39 hospitals across 9 states.

96.68% of shareholders and a significant majority of creditors voted in favor of the merger scheme.
The combined entity will operate 39 hospitals with 10,625+ beds across 9 states and 28 cities.
Merger is on track for completion in the next quarter, pending final statutory NCLT approvals.
The transaction creates one of India's top three hospital chains, supported by Blackstone's institutional expertise.
The combined workforce will exceed 36,307 employees and clinicians serving millions of patients annually.

💡 Investors should view this as a major positive milestone that significantly enhances the company's market share and scale. Monitor the final NCLT approval and the subsequent integration for potential operational synergies and margin improvements.

Aster DM Shareholders Approve Amalgamation with Quality Care India with 96.68% Majority

🟢 POSITIVE ⭐ 9/10

M&A 📅 11 Mar 2026, 10:04 PM

Shareholders of Aster DM Healthcare have officially approved the Scheme of Amalgamation with Quality Care India Limited (QCIL) in an NCLT-convened meeting held on March 10, 2026. The resolution saw high participation with 93% of outstanding shares being polled. A significant majority of 96.68% of total votes were cast in favor of the merger, satisfying the requirements of both the Companies Act and SEBI regulations. This approval marks a major milestone in the company's structural consolidation process.

Total votes polled reached 48.18 crore, representing 93.00% of the total outstanding shares.
The merger resolution was approved by 96.68% of the total votes cast.
Public institutional shareholders supported the move with 92.76% of their votes in favor.
Public non-institutional shareholders showed near-unanimous support with 99.99% voting in favor.
The scheme involves the merger of Quality Care India Limited (Transferor) into Aster DM Healthcare (Transferee).

💡 Investors should view this overwhelming shareholder approval as a positive step toward the company's growth and consolidation strategy. Monitor the final NCLT sanction and subsequent integration updates for long-term value creation.

Aster DM Appoints Founder Dr. Azad Moopen as Executive Director until May 2028

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 10 Mar 2026, 07:01 PM

The Board of Aster DM Healthcare has approved the appointment of its founder, Dr. Azad Moopen, as an Executive Director effective from April 15, 2026, through May 28, 2028. This role is a redesignation from his current position as Managing Director, though he will continue to serve as the Chairman of the Company. The appointment is subject to shareholder approval via a postal ballot. This move is intended to ensure leadership continuity and leverage Dr. Moopen's decades of institutional knowledge and operational expertise.

Dr. Azad Moopen appointed as Executive Director for a term from April 15, 2026, to May 28, 2028
Redesignated from Managing Director while retaining his position as Chairman of the Board
Appointment requires final approval from shareholders through a postal ballot process
Dr. Moopen has been associated with the company since its establishment in 1987
Leadership team includes family members Ms. Alisha Moopen (Deputy MD) and Dr. Zeba Azad Moopen (Non-Executive Director)

💡 Investors should view this as a positive step for leadership stability and continuity of the company's strategic vision. No immediate action is required as the founder remains at the helm of the organization.

Aster DM Healthcare Holds Creditors Meeting for Merger with Quality Care India

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Mar 2026, 06:56 PM

Aster DM Healthcare convened a meeting of its unsecured trade creditors on March 10, 2026, to seek approval for the Scheme of Amalgamation with Quality Care India Limited. The meeting was held via video conferencing as directed by the NCLT Hyderabad bench, with 51 creditors in attendance. Remote e-voting was conducted between March 6 and March 9, 2026, to facilitate the approval process. The company is now awaiting the final scrutinizer's report to disclose the voting results to the exchanges.

Meeting of unsecured trade creditors held on March 10, 2026, regarding the merger with Quality Care India Limited.
A total of 51 unsecured trade creditors participated in the NCLT-convened proceedings.
Remote e-voting was active from March 6, 2026 (9:00 AM) to March 9, 2026 (5:00 PM).
The amalgamation scheme is part of a strategic consolidation between the Transferor and Transferee companies.

💡 Investors should watch for the official voting results to confirm creditor approval, which is a critical milestone for the merger. Successful amalgamation is expected to bring operational synergies and scale to Aster DM's healthcare portfolio.

Aster DM Shareholders Meet to Approve Merger with Quality Care India Limited

🟢 POSITIVE ⭐ 8/10

M&A 📅 10 Mar 2026, 06:53 PM

Aster DM Healthcare held an NCLT-convened meeting on March 10, 2026, to seek shareholder approval for the amalgamation of Quality Care India Limited into the company. The meeting was attended by 64 members via video conferencing and was chaired by an NCLT-appointed advocate. Management addressed shareholder queries regarding the rationale and salient features of the proposed scheme. The final voting results, including remote e-voting conducted between March 6-9, 2026, will be disclosed within the prescribed regulatory timelines.

NCLT-convened meeting held on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited.
Remote e-voting period concluded on March 9, 2026, at 5:00 P.M. IST prior to the general meeting.
A total of 64 members participated in the meeting through Video Conferencing and Other Audio Visual Means.
The scheme involves Quality Care India Limited as the Transferor Company and Aster DM Healthcare as the Transferee Company.
Final voting results and the Scrutinizer's report are expected to be disseminated to BSE and NSE shortly.

💡 Investors should watch for the official voting results to confirm shareholder approval of the merger. Successful amalgamation is expected to consolidate operations and potentially enhance long-term value.

Aster DM Merger with Quality Care to Create Top 3 Hospital Chain; 10-15% EBITDA Synergy Expected

🟢 POSITIVE ⭐ 10/10

M&A 📅 02 Mar 2026, 03:25 PM

Aster DM Healthcare is advancing its merger with Quality Care India Limited to create one of India's top three hospital chains. The combined entity will operate across 9 states and 25 cities, serving approximately 2.0 million patients per quarter. Management expects the merger to generate an EBITDA upside of 10-15% through operational synergies. To address governance concerns, promoters have committed to waiving board nomination rights if their shareholding drops below 10%.

Merger creates a top 3 Indian hospital chain with 6,690+ clinicians and presence in 25 cities.
Identified synergies expected to provide an EBITDA upside potential of 10-15% of FY24 pro-forma EBITDA.
Shareholders previously approved the preceding Share Swap with an overwhelming 99.998% majority.
Promoters (Aster and Blackstone) committed to governance reforms, including waiving committee nomination rights.
Final equity shareholder meeting for scheme approval scheduled for March 10, 2026.

💡 Investors should view this as a major growth catalyst that significantly scales the company's footprint and margin profile. Monitor the final voting results from the March 10 meeting to confirm the merger's progression.

Aster DM Signs SHA for Sarjapur Subsidiary to Facilitate Fundraising via CCPS

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 26 Feb 2026, 07:21 PM

Aster DM Healthcare has entered into a Shareholders' Agreement (SHA) with its wholly-owned subsidiary, Aster DM Super-specialty Hospital (Sarjapur) Private Limited. The agreement is a strategic step to facilitate the subsidiary's plan to raise capital from external investors through Compulsorily Convertible Preference Shares (CCPS). The SHA ensures Aster DM retains significant governance control, including board nomination rights and a call option on shares held by future minority investors. This move indicates a focused expansion strategy for the Sarjapur facility using external capital.

Aster DM Healthcare signed a Shareholders' Agreement with its Sarjapur subsidiary on February 26, 2026.
The Sarjapur entity intends to raise funds from potential investors through the issuance of Compulsorily Convertible Preference Shares (CCPS).
Aster DM retains the right to nominate directors and holds a call option on shares held by other future shareholders.
The agreement includes strict share transfer restrictions and lock-in periods for potential external investors.
The transaction is conducted at arm's length and does not currently constitute a related party transaction under SEBI regulations.

💡 Investors should view this as a positive step toward capital-efficient expansion of the Sarjapur facility. Monitor for future announcements regarding the specific amount raised and the identity of the incoming investors to gauge valuation benchmarks.

Aster DM Healthcare to Participate in Kotak Investor Conference on Feb 24, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 05:17 PM

Aster DM Healthcare Limited has scheduled its participation in the Kotak Investor Conference on February 24, 2026. The company will engage with institutional investors and analysts through both group and one-on-one meetings. The event is a physical conference held in Mumbai from 10:00 AM to 5:00 PM IST. This is a standard regulatory disclosure, and the company has confirmed that no unpublished price sensitive information will be shared during these sessions.

Participation in Kotak Investor Conference scheduled for February 24, 2026
Meeting format includes both Investor Group and One-on-One sessions
Physical event to be held in Mumbai from 10:00 AM to 5:00 PM IST
Company confirms no unpublished price sensitive information (UPSI) will be disclosed

💡 No immediate action is required as this is a routine investor relations event. Investors may monitor the exchange filings for any investor presentations released in conjunction with the conference.

Aster DM Healthcare to Participate in Kotak Investor Conference on February 24, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 05:15 PM

Aster DM Healthcare Limited has announced its participation in the Kotak Investor Conference scheduled for February 24, 2026. The event will be held physically in Mumbai from 10:00 AM to 5:00 PM IST. The company's representatives will engage in both group and one-on-one meetings with institutional investors. This is a standard regulatory disclosure under SEBI Regulations, and the company has confirmed that no unpublished price sensitive information will be shared.

Participation in Kotak Investor Conference on February 24, 2026
Meetings scheduled from 10:00 AM to 05:00 PM IST in Mumbai
Format includes both Investor Group and One-on-One interactions
Disclosure made pursuant to Regulation 30 of SEBI LODR Regulations

💡 No immediate action is required as this is a routine investor relations event. Investors may look for any subsequent investor presentations or transcripts that might be released following the conference for updates on business outlook.

Aster DM Q3 FY26: Combined Revenue up 15% to ₹2,366 Cr; QCIL Merger on Track for Q1 FY27

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 09 Feb 2026, 03:54 PM

Aster DM reported a 15% YoY growth in combined proforma revenue to ₹2,366 crore for Q3 FY26, with operating EBITDA rising 22% to ₹503 crore. The merger with Quality Care India Limited (QCIL) is progressing well, with NCLT approval expected by Q1 FY27, which will create a platform with over 14,710 beds. Standalone revenue grew 13% to ₹1,186 crore, supported by a 9% increase in inpatient ARPP and strong growth in Oncology and Medical Value Travel. The company maintained a healthy combined ROCE of 21% while continuing aggressive expansion plans.

Combined proforma revenue grew 15% YoY to ₹2,366 crore with a 21% EBITDA margin.
Aster standalone revenue increased 13% to ₹1,186 crore, while Oncology revenue surged 27% YoY.
The merger with QCIL is on track for Q1 FY27 completion, following CCI and stock exchange approvals.
Total combined bed capacity reached 10,620+ with a pipeline to add 4,000+ more beds.
Medical Value Travel (MVT) segment grew 41% YoY, driven by a 64% increase in international footfall in Kerala.

💡 Investors should monitor the upcoming shareholder meeting in late February for the QCIL merger approval, as the combined entity shows superior margins and ROCE. The stock remains a strong play on hospital consolidation and specialty mix improvement in the Indian healthcare sector.

Aster DM Healthcare to Participate in Investor Conference on February 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 04:03 PM

Aster DM Healthcare Limited has announced its participation in an upcoming investor conference scheduled for February 11, 2026, in Mumbai. The engagement will feature both group and one-on-one meetings between 10:00 AM and 5:00 PM IST. This disclosure is a routine regulatory filing under SEBI Regulation 30 to ensure transparency regarding institutional interactions. The company has explicitly stated that no unpublished price sensitive information will be shared during these sessions.

Investor conference scheduled for February 11, 2026, in Mumbai.
Meeting format includes both Group and One-on-One interactions.
Scheduled timing is from 10:00 AM to 05:00 PM IST.
Compliance with SEBI (LODR) Regulations 2015 for investor disclosures.

💡 Investors should monitor for any investor presentations or transcripts released after the event for insights into the company's outlook. No immediate action is required as this is a routine corporate communication.

Aster DM to Merge with Quality Care to Create India's Top 3 Hospital Chain with 10,625+ Beds

🟢 POSITIVE ⭐ 10/10

M&A 📅 05 Feb 2026, 09:43 AM

Aster DM Healthcare has announced a major merger with Blackstone-backed Quality Care India Limited (QCIL) to create a healthcare powerhouse with over 10,625 beds. The combined entity, to be named Aster DM Quality Care Limited, reported a proforma 9MFY26 revenue of INR 6,913 Cr and an Operating EBITDA of INR 1,496 Cr with a 21.6% margin. The transaction values Aster at 36.6x FY24 Adj. EBITDA, representing a 45% premium over the multiple ascribed to QCIL. The merger is expected to be EPS accretive from the first full year of operations and will be jointly controlled by Aster promoters and Blackstone.

Merged entity will have 10,625+ capacity beds across 9 states and 28 cities, operating under brands like Aster, CARE Hospitals, and KIMSHEALTH.
Combined 9MFY26 financial performance shows a healthy Operating EBITDA margin of 21.6% and a RoCE of 20.7%.
Aster DM standalone 9MFY26 revenue grew to INR 3,461 Cr with ARPOB increasing to INR 51,100 from INR 44,200 YoY.
Post-merger shareholding structure will be Aster Promoters (24%), Blackstone (30.7%), and Public/Others (45.3%).
The transaction is cash-neutral and involves a share swap ratio of 977 Aster shares for every 1,000 QCIL shares.

💡 Investors should view this as a transformative growth milestone that significantly enhances Aster's market position and geographical footprint. The institutional backing from Blackstone and the expected EPS accretion make this a strong long-term play in the Indian healthcare sector.

Aster DM Healthcare Schedules Creditors Meeting on March 10 for Merger with Quality Care India

🟢 POSITIVE ⭐ 8/10

M&A 📅 04 Feb 2026, 08:23 PM

Aster DM Healthcare has convened a meeting of its unsecured trade creditors on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited (QCIL). This meeting follows directions from the NCLT Hyderabad Bench and previous 'no-objection' clearances from BSE and NSE received in October 2025. Creditors as of the October 31, 2025, cut-off date will participate in e-voting between March 6 and March 9, 2026. This merger is a significant step in consolidating the company's healthcare footprint in India.

Meeting of Unsecured Trade Creditors scheduled for March 10, 2026, at 2:00 PM IST via VC/OAVM.
Merger involves Aster DM Healthcare Limited and Quality Care India Limited (QCIL).
Remote e-voting period is set from March 6, 2026, to March 9, 2026, for eligible creditors.
The cut-off date for determining voting rights based on outstanding dues is October 31, 2025.
The scheme previously received 'no adverse observation' letters from NSE and BSE on October 6, 2025.

💡 Investors should view this as a positive procedural milestone in the merger process which aims to create a larger healthcare entity. Monitor the outcome of the creditors' meeting as it is a prerequisite for final NCLT approval.

View All ASTERDM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The core Hospitals and Clinics segment, which contributes 94% of total revenue, grew 10% YoY in Q2 FY26 to INR 1,160 Cr. Aster Labs revenue grew 15% YoY in Q2 FY26, while the Pharmacy business saw a revenue decrease to INR 134 Cr in FY25 from INR 168 Cr in FY24 due to a strategic exit from loss-making wholesale units.

Geographic Revenue Split

Operations are heavily concentrated in South India, with key clusters in Kerala, Karnataka, Andhra Pradesh, and Telangana. Kerala remains a primary market, showing steady recovery and contributing significantly to the 20% revenue CAGR over the last five years.

Profitability Margins

Operating Profit Margin (OPM) improved to 18.7% in FY25 from 15.9% in FY24. In Q2 FY26, the margin reached 22.0%, up from 21.4% in Q2 FY25. Normalised PAT (Post-NCI) for Q2 FY26 was INR 110 Cr, a 14% increase YoY from INR 97 Cr.

EBITDA Margin

Operating EBITDA margin stood at 22.0% in Q2 FY26, a 53 bps improvement YoY. Core hospital business delivered a higher margin of 24.4%, while matured hospitals achieved 26.5% in Q2 FY26. EBITDA grew 13% YoY to INR 263 Cr in Q2 FY26.

Capital Expenditure

Planned capital expenditure of approximately INR 2,500 Cr to add 2,600 beds by FY2029, with INR 400 Cr already incurred as of June 30, 2025. An additional INR 900-1,000 Cr is allocated for incremental bed capacity and maintenance between FY24 and FY26.

Credit Rating & Borrowing

ICRA upgraded ratings on bank lines totaling INR 602 Cr. Total debt as of March 31, 2025, was INR 2,017.8 Cr (including INR 1,375.6 Cr in lease liabilities). Net Debt/EBITDA improved significantly to 0.8x following the GCC business sale proceeds.

⚙️ Operational Drivers

Raw Materials

Primary costs include medical consumables, pharmaceuticals (representing the bulk of the 6% revenue from labs/pharmacy), and medical equipment. Specific percentage of total cost per item is not disclosed.

Import Sources

Not specifically disclosed in available documents, though medical equipment is noted as a key investment area for capacity expansion.

Capacity Expansion

Current capacity is 5,159 beds (FY25). The company plans to add 2,300+ beds to reach a total capacity of 7,800+ beds, with 234 beds in FY26, 1,054 in FY27, and 1,080 beyond FY27.

Raw Material Costs

Not disclosed as a specific percentage of revenue, but procurement synergies and group-strength negotiations are used to manage costs. Pharmacy business strategic exits were made to improve overall profitability.

Manufacturing Efficiency

Occupancy stood at 62% in FY25. Average Revenue Per Occupied Bed (ARPOB) increased 12% YoY to INR 45,000 in FY25. Average Length of Stay (ALOS) improved to 3.2 days from 3.4 days.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be driven by adding 2,300+ beds by FY27, optimizing the payor mix (currently 81% cash and insurance), and expanding the O&M asset-light model in emerging regional cities. The company is also integrating with Quality Care India Limited (QCIL) to create a merged entity with 7,800+ capacity beds.

Products & Services

Quaternary and tertiary healthcare services, oncology treatments (grew 26% YoY), diagnostic lab tests, and retail/wholesale pharmacy products.

Brand Portfolio

Aster DM Healthcare, Aster Medcity, Aster MIMS, Aster Whitefield, Aster Aadhar, Aster Labs, and Aster Health App.

New Products/Services

The Aster Health App, launched in November 2024, has achieved over 100,000 downloads to enhance digital patient engagement.

Market Expansion

Expansion into Northern Kerala (Kasargod) and deeper penetration into Karnataka, Maharashtra, Andhra Pradesh, and Telangana clusters.

Strategic Alliances

Merger with Quality Care India Limited (QCIL) to scale operations to a proforma revenue of INR 2,390 Cr for the merged entity.

🌍 External Factors

Industry Trends

The industry is shifting toward high-acuity and complex care in urban centers. Aster has positioned itself with a 20% revenue CAGR and 38% EBITDA CAGR over 5 years, outperforming general market growth through quaternary care focus.

Competitive Landscape

Faces competition from regional hospital chains in South India and national players; competitive pressure is a noted risk for geographic concentration.

Competitive Moat

Moat is built on a strong brand presence in South India, high-end quaternary care capabilities (e.g., Aster Medcity), and an established referral network from the GCC region. These are sustainable due to high switching costs in complex healthcare and long-term doctor-patient relationships.

Macro Economic Sensitivity

Sensitive to medical tourism trends, particularly from GCC countries to Indian hospitals, which helps mitigate regional economic risks.

Consumer Behavior

Increasing demand for digital healthcare convenience, addressed by the launch of the Aster Health App.

Geopolitical Risks

The segregation of the GCC business reduces direct exposure to Middle Eastern geopolitical shifts, though the brand remains leveraged in that region for medical tourism.

⚖️ Regulatory & Governance

Industry Regulations

Subject to price-control measures and high compliance standards for healthcare services. Recent CGHS price increases for 2,000+ procedures provided a positive revenue impact of INR 2 Cr per month.

Taxation Policy Impact

FY24 results excluded a one-time impact of INR 52.4 Cr due to the recognition of Net Deferred Tax Liability.

Legal Contingencies

The company faces moderate social risks including litigation exposure and high compliance requirements typical of the healthcare sector. Specific case values are not disclosed.

⚠️ Risk Analysis

Key Uncertainties

Regulatory price caps and changes in government healthcare schemes (CGHS/ESI) could impact margins by 35-40 basis points of EBITDA.

Geographic Concentration Risk

High dependence on South India; regional economic downturns or regulatory changes in Kerala or Karnataka could significantly impact the 94% revenue share from hospitals.